NOVENA · Exploiting an unusual polyketide chain release mechanism for production of novel enacyloxin antibiotic analogues
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2015-06-01 → 2017-05-31
- Финансиране от ЕС
- 195 455 €
- Участници
- 1
- Схема
- MSCA-IF-EF-ST
Линиите свързват координатора с партньорите.
Накратко на български
Механизмът за създаване на антибиотика енацилоксин и негови нови analogue се анализират чрез модифициране на бактерията Burkholderia ambifaria. Това помага за разработването на по-стабилни лекарства срещу опасни болнични бактерии като Acinetobacter baumannii.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Exploiting an unusual polyketide chain release mechanism for production of novel enacyloxin antibiotic analogues
Enacyloxin IIa is a polyketide antibiotic with activity against Gram-positive and Gram-negative bacteria that targets ribosomal elongation factor Tu. It has recently been identified as metabolite of Burkholderia ambifaria and shown to have clinically-relevant activity against Acinetobacter baumannii, a problematic panresistant Gram-negative pathogen that is estimated to account for 2-10% of all Gram-negative bacterial infections in intensive care units in Europe and for the death of thousands of European hospital patients every year. Despite its promising biological activity, enacyloxin IIa has not been used in the clinic, presumably due to stability issues. Preliminary experiments have provided evidence for an unusual mechanism of modular polyketide synthase chain release in enacyloxin biosynthesis, involving intermolecular condensation of an acyl carrier protein (ACP)-bound thioester with the C-3 hydroxyl group of (1S, 3R, 4S)-3,4- dihydroxycyclohexane carboxylic acid (DHCCA). This project aimed to elucidate and engineer the biosynthetic pathway to enacyloxin. It also aimed to illuminate the structure-activity relationship of the antibiotic by studying the characteristics of the enacyloxin analogues generated. The specific objectives of the project were: (1) Identify the enzyme responsible for epimerisation of C-1 of the DHCCA moiety (2) Explore the ability of the Bamb_5915 chain release enzyme to catalyse the acylation of diverse DHCCA analogues (3) Create a Burkholderia ambifaria mutant blocked in DHCCA biosynthesis (4) Produce novel enacyloxin IIa derivatives via a mutasynthesis approach involving feeding of DHCCA analogues to a B. ambifaria mutant blocked in DHCCA biosynthesis. The project was highly successful in its aims and fully reached its objectives. The unusual mechanism for polyketide chain release in the biosynthesis of enacyloxin was biochemically characterized and the role of several tailoring enzymes was elucidated. Based on these results, different biosynthetic engineering approaches were developed which afforded over a dozen enacyloxin derivatives, with the potential to yield many more.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Enacyloxin IIa is a polyketide antibiotic with activity against Gram-positive and Gram-negative bacteria that targets ribosomal elongation factor Tu. It has recently been identified as metabolite of Burkholderia ambifaria AMMD and shown to have clinically-relevant activity against Acinetobacter baumannii, a problematic pan-resistant Gram-negative pathogen. Despite its promising biological activity, enacyloxin IIa has not been used in the clinic, presumably due to stability issues. Preliminary experiments have provided evidence for an unusual mechanism of modular polyketide synthase chain release in enacyloxin biosynthesis, involving intermolecular condensation of an acyl carrier protein (ACP)-bound thioester with the C-3 hydroxyl group of (1R, 3R, 4S)-3,4-dihydroxycyclohexane carboxylic acid (DHCCA). The resulting intermediate undergoes epimerisation at C-1 of the DHCCA moiety. This project aims to explore the ability of the chain release enzyme to catalyse the acetylation of a variety of DHCCA analogues with an acetyl-ACP analogue of the polyketide thioester intermediate. It also aims to identify the enzyme responsible for epimerising C-1 of the DHCCA moiety. DHCCA biosynthetic genes will be deleted in B. ambifaria and enacyloxin analogues, with a stable amide group in place of the labile ester group and other modifications to the DHCCA-derived moiety, will be produced via a mutasynthesis strategy.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITY OF WARWICK · COVENTRYКоординаторОбединеното кралство
Връзки
- Виж в CORDIS
- DOI: 10.3030/656067
- http://www2.warwick.ac.uk/fac/sci/chemistry/research/challis/challisgroup
Данни: CORDIS, © Европейски съюз
